MAA submitted to the EMA for Zepzelca® (lurbinectedin) + Tecentriq for the maintenance treatment of adult patients with ES-SCLC May 27, 2025
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib May 27, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
CHMP recommends EU approval of Itovebi for PIK3CA-mutated, ER+ve, HER2-neg, advanced breast cancer May 27, 2025
Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer May 27, 2025
First Patient Dosed in TNG456 Ph 1/2 Trial in Patients With MTAP-deleted GBM and Other Solid Tumors May 27, 2025
Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025
FDA ODAC votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma May 27, 2025
OSE Immunotherapeutics, Inside Therapeutics, and Angers-based MiNT Laboratory to develop mRNA therapeutics and accelerate nanodrug development May 27, 2025
Helix BioPharma Secures Pre-IND Candidates LEUMUNA™ and GEMCEDA™ in Strategic Acquisition from the Laevoroc Group May 27, 2025
Monotherapy and combo arms of BBI-355 in POTENTIATE trial to be discontinued; BBI-355 – BBI-825 combo to be investigated May 27, 2025
NMPA CDE grants Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC May 27, 2025
Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with R/R B-ALL May 27, 2025
FDA ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC May 27, 2025
FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab + Chemo for Patients With R/R DLBCL May 27, 2025
NMPA approves Minjuvi (Tafasitamab) + Lenalidomide for the treatment of Adult Patients with R/R DLBCL in China May 27, 2025
